Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
Introduction Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. Case presentation A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg a...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-07-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.12073 |